Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress
Gossamer Bio (NASDAQ: GOSS) presented clinical and preclinical data for seralutinib at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress in Rio de Janeiro, Brazil. The presentations included one oral presentation and three posters focusing on seralutinib, an inhaled PDGFR, CSF1R and c-KIT inhibitor being developed for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The posters covered preclinical models demonstrating synergistic potential with sotatercept, sustained benefits observed in the TORREY open-label extension study, and the drug's sustained effect on circulating biomarkers.
Gossamer Bio (NASDAQ: GOSS) ha presentato dati clinici e preclinici per seralutinib al Congresso Annuale dell'Istituto di Ricerca Vascolare Polmonare (PVRI) 2025 a Rio de Janeiro, Brasile. Le presentazioni hanno incluso una presentazione orale e tre poster incentrati su seralutinib, un inibitore inalato di PDGFR, CSF1R e c-KIT in fase di sviluppo per l'ipertensione arteriosa polmonare (PAH) e l'ipertensione polmonare associata a malattie polmonari interstiziali (PH-ILD).
I poster hanno trattato modelli preclinici che dimostrano il potenziale sinergico con sotatercept, i benefici sostenuti osservati nello studio esteso in aperto TORREY, e l'effetto sostenuto del farmaco sui biomarcatori circolanti.
Gossamer Bio (NASDAQ: GOSS) presentó datos clínicos y preclínicos para seralutinib en el Congreso Anual del Instituto de Investigación Vascular Pulmonar (PVRI) 2025 en Río de Janeiro, Brasil. Las presentaciones incluyeron una presentación oral y tres carteles centrados en seralutinib, un inhibidor inhalado de PDGFR, CSF1R y c-KIT que se está desarrollando para la hipertensión arterial pulmonar (PAH) y la hipertensión pulmonar asociada con enfermedades pulmonares intersticiales (PH-ILD).
Los carteles cubrieron modelos preclínicos que demuestran un potencial sinérgico con sotatercept, los beneficios sostenidos observados en el estudio de extensión abierto TORREY, y el efecto sostenido del fármaco en los biomarcadores circulantes.
Gossamer Bio (NASDAQ: GOSS)는 브라질 리오데자네이루에서 열린 2025년 폐혈관 연구소(PVRI) 연례 학회에서 seralutinib의 임상 및 전임상 데이터를 발표했습니다. 발표에는 seralutinib에 대한 구두 발표와 세 개의 포스터가 포함되었으며, 이는 폐동맥 고혈압(PAH) 및 간질성 폐 질환(PH-ILD)과 관련된 폐고혈압에 대해 개발 중인 흡입형 PDGFR, CSF1R 및 c-KIT 억제제입니다.
포스터는 sotatercept와의 시너지 잠재력을 보여주는 전임상 모델, TORREY 공개 연장 연구에서 관찰된 지속적인 혜택, 순환 바이오마커에 대한 약물의 지속적인 효과를 다루었습니다.
Gossamer Bio (NASDAQ: GOSS) a présenté des données cliniques et précliniques pour seralutinib lors du Congrès Annuel de l'Institut de Recherche Vasculaire Pulmonaire (PVRI) 2025 à Rio de Janeiro, au Brésil. Les présentations comprenaient une présentation orale et trois affiches axées sur seralutinib, un inhibiteur inhalé de PDGFR, CSF1R et c-KIT, en cours de développement pour l'hypertension artérielle pulmonaire (PAH) et l'hypertension pulmonaire associée aux maladies pulmonaires interstitielles (PH-ILD).
Les affiches ont couvert des modèles précliniques démontrant un potentiel synergique avec sotatercept, des bénéfices durables observés dans l'étude d'extension en ouvert TORREY, et l'effet durable du médicament sur les biomarqueurs circulants.
Gossamer Bio (NASDAQ: GOSS) hat klinische und präklinische Daten zu seralutinib auf dem Jahreskongress des Pulmonary Vascular Research Institute (PVRI) 2025 in Rio de Janeiro, Brasilien präsentiert. Die Präsentationen umfassten einen mündlichen Vortrag und drei Poster, die sich auf seralutinib konzentrierten, einen inhalierten Hemmer von PDGFR, CSF1R und c-KIT, der für pulmonale arterielle Hypertonie (PAH) und pulmonale Hypertonie im Zusammenhang mit interstitiellen Lungenerkrankungen (PH-ILD) entwickelt wird.
Die Poster behandelten präklinische Modelle, die ein synergetisches Potenzial mit sotatercept aufzeigen, die anhaltenden Vorteile im TORREY-Studie zur offenen Verlängerung und die anhaltende Wirkung des Medikaments auf zirkulierende Biomarker.
- Preclinical data shows synergistic potential between seralutinib and sotatercept in PAH treatment
- Sustained benefits demonstrated in TORREY open-label extension study
- Positive biomarker data showing sustained effects from Phase 2 study
- None.
Posters Related to Seralutinib, an Inhaled PDGFR, CSF1R and c-KIT Inhibitor:
Preclinical Models Support the Synergistic Potential of Seralutinib and Sotatercept in Treating Pulmonary Arterial Hypertension
Link: https://goss.bio/4h0uBJi
Sustained Benefit with Seralutinib Treatment: A Post-Hoc Analysis of the TORREY Open-Label Extension
Link: https://goss.bio/3CmVuYu
Sustained Effect of Seralutinib on Circulating Biomarkers in the TORREY Phase 2 Open-Label Extension Study
Link: https://goss.bio/42aKKqQ
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203721970/en/
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
FAQ
What did Gossamer Bio (GOSS) present at PVRI 2025 Congress?
What are the target indications for Gossamer Bio's seralutinib?
What were the key findings from GOSS's TORREY extension study?
What potential combination therapy did Gossamer Bio's preclinical data support?
